Federal Register of Legislation - Australian Government

Primary content

PB 3 of 2012 Arrangements as made
This instrument amends the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2011 (No. PB 87 of 2011) making changes to the special arangement relating to the chemotherapy pharmaceuticals access program.
Administered by: Health
Made 16 Feb 2012
Registered 23 Feb 2012
Tabled HR 27 Feb 2012
Tabled Senate 27 Feb 2012
Date of repeal 01 Apr 2012
Repealed by National Health Special Arrangement Revocation Instrument 2012 (No. PB 23 of 2012)

 

PB 3 of 2012

National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2012 (No. 1)

 

National Health Act 1953

___________________________________________________________________________

 

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 16 February 2012

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2012 (No.1).

 

(2)                This Instrument may also be cited as PB 3 of 2012.

 

2             Commencement

                This Instrument commences on 1 March 2012.

3              Amendments to PB 87 of 2011

                      Schedule 1 amends the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2011 (PB 87 of 2011).

 

 


Schedule 1                   Amendments

 

[1]    Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL with manner of administration Injection/intravesical and brand Epirubicin Ebewe

substitute:

Epirubicin

Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL

Injection/intravesical

Epirubicin Actavis 10

TA

EMP

 

 

4

0

D

 

 

 

Epirubicin Ebewe

SZ

EMP

 

 

4

0

D

 

[2]    Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL with manner of administration Injection/intravesical and brand Pharmorubicin Solution

substitute:

 

Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL

Injection/intravesical

Epirubicin Actavis 20

TA

EMP

 

 

4

0

D

 

 

 

Pharmorubicin Solution

PF

EMP

 

 

4

0

D

 

[3]    Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL with manner of administration Injection/intravesical and brand Epirubicin Ebewe

substitute:

 

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/intravesical

Epirubicin Actavis 50

TA

EMP

 

 

4

0

D

 

 

 

Epirubicin Ebewe

SZ

EMP

 

 

4

0

D

 

[4]    Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL with manner of administration Injection/intravesical and brand Epirubicin Ebewe

substitute:

 

Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

Injection/intravesical

Epirubicin Actavis 100

TA

EMP

 

 

2

0

D

 

 

 

Epirubicin Ebewe

SZ

EMP

 

 

2

0

D

 

[5]    Schedule 1, after entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL with manner of administration Injection/intravesical and brand DBL Epirubicin Hydrochloride Injection

insert in the columns in the order indicated:

 

 

 

Epirubicin Actavis 200

TA

EMP

 

 

1

0

D

 

 

 

[6]    Schedule 1, entry for Gemcitabine

omit from the column headed “Circumstances” (all instances):

C3889

C3890

C3906

C3913

C3914

 

 

[7]    Schedule 1, entry for Gemcitabine in the form Solution for injection 200 mg (as hydrochloride) in 5.3 mL

substitute:

Gemcitabine

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 5 mL

Injection

Gemcitabine Ebewe

SZ

EMP

 

 

4

2

D

 

Solution for injection 200 mg (as hydrochloride) in 5.3 mL

Injection

DBL Gemcitabine Injection

HH

EMP

 

 

4

2

D

 

[8]    Schedule 1, after entry for Gemcitabine in the form Solution for injection 1 g (as hydrochloride) in 26.3 mL

insert in the columns in the order indicated:

 

 

Solution concentrate for I.V. infusion 1 g (as hydrochloride) in 25 mL

Injection

Gemcitabine Ebewe

SZ

EMP

 

 

2

2

D

 

[9]    Schedule 1, after entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride) with manner of administration Injection and brand Gemcitabine Kabi

insert in the columns in the order indicated:

 

 

Solution concentrate for I.V. infusion 2 g (as hydrochloride) in 50 mL

Injection

Gemcitabine Ebewe

SZ

EMP

 

 

1

2

D

 

[10]  Schedule 3, omit entry for Gemcitabine

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.